Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma

Brief summary (registry, in English)

The objective of this clinical trial is to investigate the effects of Salovum®, an egg yolk powder enriched with the endogenous protein antisecretory factor, in participants undergoing diagnostic biopsies for suspected glioblastoma. The primary questions the trial seeks to answer are: * Will Salovum® reduce intratumoral pressure? * Will Salovum® influence the release of inflammatory cytokines from tumor tissue? Additionally, the study will investigate the impact of Salovum® on intratumoral partial oxygen pressure and tumor volume. Researchers will: * Place probes for measuring intratumoral pressure, microdialysis, and partial oxygen pressure during a standard biopsy procedure. * Compare measurements from participants before and during ingestion of Salovum®. Participants will: * Have probes implanted during a surgical biopsy. * Ingest Salovum® 24 to 72 hours after the procedure.

What you commit to

• Study type: Interventional · Phase 2
• Planned participants: 10
• From 7 Oct 2024 to the primary completion date, 31 Oct 2026
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.